June 2023

Incidence, Prevalence, and Co-occurrence of Autoimmune Disorders Over Time and by Age, Sex, and Socioeconomic Status: A Population-based Cohort Study of 22 Million Individuals in the UK

Lancet. 2023; 401(10391):1878–1890 doi 10.1016/S0140-6736(23)00457-9

Incidence rates for autoimmune diseases increased between 2000 and 2019 in the UK, notably in coeliac disease, Sjogren's syndrome, and Graves' disease. Pernicious anaemia and Hashimoto's thyroiditis had the greatest decrease in incidence. These disorders affected about 10% of the population, with socioeconomic, seasonal, and regional variations observed.

Keywords:

May 2023

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967

A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.

Keywords:

Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study

Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9

Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.

Keywords:

April 2023

When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?

Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007

Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.

Keywords:

Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance

Ann Rheum Dis. 2023;82(7):901-910 doi: 10.1136/ard-2022-223715

Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.

Keywords:

Incidence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640

Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).

Keywords:

Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study

Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6

Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.

Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib: A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension

RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718

Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.

Keywords:

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

ACR Open Rheumatol. 2023;5(4):227–240 doi 10.1002/acr2.11537

Post hoc analysis of guselkumab, Phase 3 DISCOVER-1 and -2 studies finds that 75% of guselkumab-randomised patients have complete resolution of dactylitis through one year.

Keywords:

Efficacy of Secukinumab on Dactylitis in Patients with Active Psoriatic Arthritis from the FUTURE 5 study

Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/vezf95

The presence of dactylitis was associated with a higher disease burden in patients with PsA compared with those without dactylitis at baseline. The aim of this study was to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.

Keywords: